Biotech SF

San Francisco Bay Area biotech stories.

Tuesday, February 1, 2011

Medical device maker Spiracur raises $35 million

Posted by Unknown at 8:45 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: De Novo Ventures, Kleiner Perkins Caufield Byers, Maverick Capital, New Leaf Venture Partners, Spiracur

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

TOP STORIES

  • Patients' tales, biotech legends add weight to BayBio awards
    Genentech co-founder Herb Boyer. When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We'...
  • Report: Health care in S.F. a 'sleeping giant,' but biotechs constrained
    San Francisco’s surging biotech industry feeds off a network of research institutions, but lease rates and city red tape remain obstacles to...
  • J&J 'bridges the gap,' funds promising QB3 research
    (San Francisco Business Times subscription required.) Two projects — including one aimed at developing an artificial pancreas that would el...
  • InterWest adds Visiogen founder Zadno to medical devices team
    InterWest Partners added Dr. Reza Zadno as a venture partner to its medical devices team. The Menlo Park-based venture capital firm speciali...
  • Stanford researchers launch brain cancer study using Nektar drug
    A team of  Stanford University  researchers will test a  Nektar Therapeutics Inc.  drug in a Phase II trial aimed at a common and aggress...

Some of my favorite stories.

• "The fight of his life" (2007)
Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)
Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)
Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)
Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.
All he needs now is $20 million.

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

Blog Archive

  • ►  2012 (486)
    • ►  November (18)
    • ►  October (25)
    • ►  September (56)
    • ►  August (56)
    • ►  July (64)
    • ►  June (26)
    • ►  May (40)
    • ►  April (39)
    • ►  March (31)
    • ►  February (74)
    • ►  January (57)
  • ▼  2011 (772)
    • ►  December (54)
    • ►  November (40)
    • ►  October (65)
    • ►  September (74)
    • ►  August (48)
    • ►  July (44)
    • ►  June (60)
    • ►  May (70)
    • ►  April (80)
    • ►  March (81)
    • ▼  February (77)
      • Melanoma drug developer Plexxikon to be sold for $...
      • Nile Therapeutics inks deal with Medtronic for hea...
      • Varian to repurchase $280M in stock
      • WaferGen puts USC researcher Timothy Triche on board
      • Doctors not pushing Truvada to prevent HIV — and t...
      • Zcube strikes deal with UCSF for microtechnology d...
      • UCSF receives $48M gift for lung research and trea...
      • Sangamo shoots up ahead of HIV data
      • Merck plans big biotech push in Palo Alto
      • Cutting-edge prostate cancer treatments could resc...
      • Genomic Health counsel helps health tests clear ro...
      • DuPont brings deep pockets to Genencor
      • Pearl Therapeutics taps Chuck Bramlage as CEO
      • Bio-Rad Labs earns $68M in Q4, $185M for year
      • Avastin gets FDA hearing in June
      • Could QB3, other UC institutes find seat at Califo...
      • Amyris inks perfume deal with Switzerland's Givaudan
      • Amyris fermentation process works on big scale
      • Anthera Q4 loss balloons to $13M on clinical trial...
      • Aurora Algae moving to Hayward
      • Stanford lands $5 million grant for center focused...
      • Universal flu vaccine working well in early test —...
      • Gilead to buy Calistoga Pharmaceuticals for $375M
      • UC biochemist Michael Marletta to head Scripps Res...
      • MIT snags UCSF synthetic biology expert Chris Voig...
      • UC-business accelerator QB3 turns 10, hopes to spr...
      • Grad students signal startup sea change
      • CPAC adds jobs, shrinks proton therapy technology
      • Second time around is charm for Aragen Bioscience
      • Map Pharmaceuticals names Scott Ward as chairman
      • Impax generic antibiotic wins FDA approval
      • Impax Labs inks $50M credit facility with Wells Fargo
      • Stanford OKs $21 million center for translating ca...
      • Debt conversion pushes BioMarin to $12.2M in Q4 loss
      • Research Track: Salmonella to new anti-viral treat...
      • Ex-CEO Thomas Okarma departing Geron with $1.3 mil...
      • UCSF Down Syndrome researcher Charles Epstein, dir...
      • As Genzyme and Sanofi marry, BioMarin looks at big...
      • Drug rights sales pushes InterMune to $206M Q4 profit
      • 2 companies cut deal, take in cash from Index Vent...
      • Ivivi Health raises $4M, converts $5.5M loan to eq...
      • Obama budget plan puts biotech drug protection on ...
      • Cytokinetics loses $11.6M in Q4
      • Sunesis Pharmaceuticals plans 1-for-6 reverse stoc...
      • UCSF ranked 3rd in NIH funding in 2010; tops for d...
      • Sonoma Orthopedic Products raises $22 million
      • Abaxis invests $2.8M into veterinary company
      • Genentech's Lucentis does well in study of diabeti...
      • Natus Medical names president/COO
      • Cytokinetics makes board changes
      • Wareham preps site for lab building in Emeryville
      • AcelRx IPO raises $40 million
      • Plenty of work ahead, but HIV becomes a model for ...
      • Revamped Novartis in Emeryville expanding off Chir...
      • As Novartis hires, construction could follow
      • Shorenstein plans to sell FibroGen's Mission Bay home
      • Codexis spots market in laundry
      • Plenty of work ahead, but HIV research becomes a m...
      • Gilead refiles for FDA approval of HIV drug with T...
      • Anacor to get up to $160M in Medicis acne deal
      • Fluidigm prices IPO at $13.50 per share
      • UCSF opens $123 million stem cell research facility
      • Geron CEO Okarma resigns
      • Trial shows Avastin helps ovarian cancer patients ...
      • Hansen Medical could get $107 million in Philips deal
      • Biotech IPO market off to busy start
      • Gilead, supplier extend tenofovir deal at least un...
      • XDx, LabCorp sign heart transplant test deal
      • IntegenX raises $15.6 million, buys GenVault
      • Komen president: Avastin position unchanged
      • Massive Health raises $2.25M for venture based on ...
      • Study links Genentech's Avastin to deadly side eff...
      • Epocrates raises $86M in IPO
      • Livermore Lab kills antibiotic-resistant bacteria ...
      • Medical device maker Spiracur raises $35 million
      • Allergan, Map Pharmaceuticals in migraine drug dea...
      • iPierian, Kyoto University patent deals clear path...
    • ►  January (79)
  • ►  2010 (59)
    • ►  December (42)
    • ►  November (17)

Search This Blog

TWITTER UPDATES

Dates to Watch

Sept. 5 - PDUFA date for Salix Pharmaceuticals' crofelemer (developed by San Francisco's Napo Pharmaceuticals) for diarrhea in HIV/AIDS patients on antiretroviral therapy.
Oct. 19 - PDUFA date for Impax Pharmaceutical's IPX-066 in Parkinson's
Oct. 23 - PDUFA date for Hyperion Therapeutics' Ravicti in urea cycle disorders.

Calendar

  • "Ushering in the New Medical Device Excise Tax: Will You Be Ready?" 8 a.m. Wednesday, Sept. 5, Abbott Vascular, 3200 Lakeside Drive, Santa Clara. Cost: $20 BayBio members, $40 non-members (through Sept. 3) and $40 members and $75 non-members (after Sept. 3)
Unknown
View my complete profile

My contact information

Ron Leuty
San Francisco Business Times
275 Battery St.,
Suite 940
San Francisco,
CA 94111
415-288-4939 - direct
415-722-2678 - cell
rleuty@
bizjournals.com
http://www.bizjournals.com/sanfrancisco

Follow me on Twitter — rleuty_biotech
— or Facebook or LinkedIn.

For biotech stories from all of ACBJ's 40 business journals — from Boston to Seattle — go to Biotech Day.

Followers

Total Pageviews
Simple theme. Powered by Blogger.